Grundinformationen
- Standard-SMILES
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+]- InChIKey
YDTFRJLNMPSCFM-YDALLXLXSA-M- Summenformel
- C15H10I4NNaO4
- Durchschnittliche Molmasse
- 798,85 g/mol
- Monoisotopische Masse
- 798,66864408
Überblick
Levothyroxine sodium anhydrous is the sodium salt of L-thyroxine. It is used as replacement therapy in the treatment of hypothyroidism. It contains a L-thyroxine(1-).
Namen und Bezeichner
- Bevorzugter Name
- Levothyroxine Sodium
- IUPAC
- sodium (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
Namen und Synonyme
Levothyroxine sodiumL-Thyroxine sodium55-03-8EuthyroxUnithroidlevothroidLevoxylNovothyroxLettersynthroidThyroxine sodiumThyroxin sodium
Weitere Namen anzeigen
Sodium thyroxinateThyroxine sodium salteltroxinSodium L-thyroxineThyronaminTirosintEferoxLevaxin
Datenbank-Bezeichner
- CAS
25416-65-3、55-03-8- PubChem CID
- 23666112
- DTXSID
DTXSID90883228- ChEMBL
CHEMBL2103741- ChEBI
CHEBI:6446- UNII
- 054I36CPMN
- EC Number
- 200-221-4、685-634-1
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 95,6 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 25
- Formalladung
- 0
- Komplexität
- 426
Experimentelle und physikochemische Eigenschaften
Human Drugs
Breast Feeding; Lactation; Milk, Human; Thyroid Hormones
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsFDA approved animal drugs -> Active ingredient
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Danger
H361 (92.5%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 53 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H361 (25%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
Gefahrenhinweise
Other Safety InformationIMAP assessments - L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt: Human health tier I assessment
Hazard Classes and Categories
Repr. 2 (92.5%)
STOT RE 1 (75%)
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Levothyroxine sodium
vLess-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Chemie und Industrie
Pharmakologische Informationen
ATC Code
H - Systemic hormonal preparations, excl. sex hormones and insulins
QH - Systemic hormonal preparations, excl. sex hormones and insulin
FDA Pharmacological Classification
LEVOTHYROXINE SODIUM
l-Thyroxine [EPC]; Thyroxine [CS]
LEVOTHYROXINE SODIUM ANHYDROUS
Thyroxine [CS]; l-Thyroxine [EPC]
Verwendung und Herstellung
UsesUse (kg) in Switzerland (2009): >5
General Manufacturing InformationL-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1): INACTIVE
Zugehörige Reaktionen
6
Verknüpfte Notizen
Wird geladen…